DK0939804T4 - Neutrokin-alpha - Google Patents

Neutrokin-alpha

Info

Publication number
DK0939804T4
DK0939804T4 DK96939612.6T DK96939612T DK0939804T4 DK 0939804 T4 DK0939804 T4 DK 0939804T4 DK 96939612 T DK96939612 T DK 96939612T DK 0939804 T4 DK0939804 T4 DK 0939804T4
Authority
DK
Denmark
Prior art keywords
neutrokine alpha
methods
neutrokine
immune system
related disorders
Prior art date
Application number
DK96939612.6T
Other languages
Danish (da)
English (en)
Other versions
DK0939804T3 (da
Inventor
Reinhard Ebner
Jian Ni
Guo-Liang Yu
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22256104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0939804(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of DK0939804T3 publication Critical patent/DK0939804T3/da
Publication of DK0939804T4 publication Critical patent/DK0939804T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
DK96939612.6T 1996-10-25 1996-10-25 Neutrokin-alpha DK0939804T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/017957 WO1998018921A1 (en) 1996-10-25 1996-10-25 NEUTROKINE $g(a)

Publications (2)

Publication Number Publication Date
DK0939804T3 DK0939804T3 (da) 2005-12-19
DK0939804T4 true DK0939804T4 (da) 2011-07-18

Family

ID=22256104

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96939612.6T DK0939804T4 (da) 1996-10-25 1996-10-25 Neutrokin-alpha

Country Status (14)

Country Link
EP (3) EP0939804B2 (enExample)
JP (1) JP2001503263A (enExample)
KR (2) KR20000052796A (enExample)
CN (1) CN1539970A (enExample)
AT (1) ATE302272T1 (enExample)
AU (1) AU731553B2 (enExample)
BR (1) BR9612752A (enExample)
CA (2) CA2266439C (enExample)
DE (1) DE69635088T3 (enExample)
DK (1) DK0939804T4 (enExample)
ES (1) ES2248823T5 (enExample)
NZ (1) NZ334309A (enExample)
PT (1) PT939804E (enExample)
WO (1) WO1998018921A1 (enExample)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
AU743490B2 (en) * 1997-06-06 2002-01-24 Regeneron Pharmaceuticals, Inc. NTN-2 member of TNF ligand family
CA2292835A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
AU9376498A (en) * 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
PL339740A1 (en) * 1997-09-12 2001-01-02 Biogen Kay - a novel immune system protein
CA2310987A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
WO2000040716A2 (en) 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
AU762839B2 (en) * 1999-01-25 2003-07-03 Apoxis Sa Baff, related blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
EP1860190A3 (en) * 1999-02-23 2008-03-12 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variants
CN100439499C (zh) * 1999-02-23 2008-12-03 人体基因组科学有限公司 Neutrokine-α和Neutrokine-α剪接变体
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
IL145676A0 (en) 1999-04-12 2002-06-30 Genentech Inc Tumor necrosis factor homologs and nucleic acids encoding the same
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
AU6338200A (en) 1999-06-28 2001-01-31 Genentech Inc. Methods for making apo-2 ligand using divalent metal ions
ATE360693T1 (de) 1999-08-17 2007-05-15 Biogen Idec Inc Baff rezeptor (bcma), ein immunoregulatorisches mittel
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
ATE521634T1 (de) 2000-02-11 2011-09-15 Biogen Idec Inc Heterologes polypeptid der tnf familie
CA2396793A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US6969519B2 (en) 2000-03-10 2005-11-29 Human Genome Sciences, Inc. Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
AU4761601A (en) 2000-04-11 2001-10-23 Genentech Inc Multivalent antibodies and uses therefor
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP2431054A3 (en) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
MXPA02012434A (es) * 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
CA2415473A1 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
AU2001288260A1 (en) * 2000-08-15 2002-03-13 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2438682A1 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
NZ542878A (en) 2001-05-11 2007-06-29 Amgen Inc Peptides and related molecules that bind to tall-1 in particular SEQ ID NO:104
KR101021124B1 (ko) 2001-05-24 2011-03-14 지모제넥틱스, 인코포레이티드 Ｔａｃｉ-면역글로불린 융합 단백질
CA2446723C (en) 2001-05-25 2014-01-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
DK1409544T3 (da) 2001-07-03 2009-10-26 Genentech Inc Humane DR4-antistoffer og anvendelser deraf
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
US20040186051A1 (en) 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
AU2002351495A1 (en) * 2001-10-17 2003-04-28 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
DE60237841D1 (de) 2001-11-13 2010-11-11 Genentech Inc Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20060141561A1 (en) 2002-06-24 2006-06-29 Kelley Robert F Apo-2 ligand/trail variants and uses thereof
AU2003299819A1 (en) * 2002-12-23 2004-07-22 Human Genome Sciences, Inc. Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
AU2004233164B2 (en) 2003-03-28 2009-10-08 Biogen Ma Inc. Truncated BAFF receptors
ES2538469T3 (es) 2003-06-05 2015-06-22 Genentech, Inc. Terapia de combinación para trastornos de células B
US20050255560A1 (en) * 2003-11-21 2005-11-17 Zeren Gao Ztnf11, a tumor necrosis factor
JP2008505607A (ja) * 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド Ｂｃｍａの細胞外ドメインの変異体とその使用法
US8168445B2 (en) 2004-07-02 2012-05-01 Bio-Layer Pty Limited Use of metal complexes
RU2410438C2 (ru) 2004-08-06 2011-01-27 Дженентек, Инк. Анализы и способы, использующие биомаркеры
ES2365719T3 (es) 2004-08-06 2011-10-10 Genentech, Inc. Ensayos y procedimientos que utilizan biomarcadores.
JP4907353B2 (ja) 2004-09-15 2012-03-28 興和株式会社 Ｂａｆｆ抑制剤又は阻害剤のスクリーニング方法
CA2580271A1 (en) 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
CA2583900A1 (en) * 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2590461A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
JP2009507777A (ja) 2005-08-09 2009-02-26 ザイモジェネティクス，インコーポレイティド ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法
EP1922079A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EP2287615A1 (en) 2005-08-16 2011-02-23 Genentech, Inc. Apoptosis sensitivity to APO2L/TRAIL by testing for GALNAC-T14 expression in cells/tissues
KR20140077946A (ko) 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
EA015342B1 (ru) 2006-05-15 2011-06-30 Арес Трейдинг С.А. Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
KR102025502B1 (ko) 2008-09-26 2019-09-25 토카겐 인크. 유전자 요법 벡터와 시토신 디아미나아제
AU2009319864A1 (en) 2008-11-25 2011-07-14 Biogen Idec Ma Inc. Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP3211094A3 (en) 2009-09-03 2017-11-01 F. Hoffmann-La Roche AG Methods for treating, diagnosing, and monitoring rheumatoid arthritis
EP2640744A4 (en) 2010-11-19 2014-05-28 Eisai R&D Man Co Ltd NEUTRALIZATION OF ANTIBODIES TO CCL20
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
JP2015506950A (ja) 2012-01-31 2015-03-05 ジェネンテック， インコーポレイテッド 抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
CN103421113B (zh) * 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 抗BLyS抗体
JP6419706B2 (ja) 2012-10-25 2018-11-07 トカジェン インコーポレーテッド ミニプロモーターカセットを含むレトロウイルスベクター
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
DE102014018663A1 (de) 2014-12-13 2015-03-05 Heinz Kiefer Nachweis von vermehrungsfähigen Zellen zur Überprüfung von Arzneimittel-Wirkstoffangaben bei Zulassungsverfahren
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
KR20230029621A (ko) 2020-05-08 2023-03-03 알파인 이뮨 사이언시즈, 인코포레이티드 T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법
CA3216795A1 (en) 2021-05-07 2022-11-10 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
CN113238061B (zh) * 2021-07-09 2021-10-01 中南大学湘雅医院 以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用
KR20250099778A (ko) 2022-10-04 2025-07-02 알파인 이뮨 사이언시즈, 인코포레이티드 자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질
CN119799684A (zh) * 2024-12-27 2025-04-11 深圳先进技术研究院 一种靶向无害梭菌的抗菌蛋白及其制备方法与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4433092A (en) 1981-03-09 1984-02-21 Champion Spark Plug Company Green ceramic of lead-free glass, conductive carbon, silicone resin and AlPO4, useful, after firing, as an electrical resistor
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE159858T1 (de) 1983-09-26 1997-11-15 Ehrenfeld Udo Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
CA1255586A (en) 1984-07-24 1989-06-13 Hendrik M. Geysen Method of determining mimotopes
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
ATE114673T1 (de) 1985-08-16 1994-12-15 Univ Rockefeller Modulator der anabolischen aktivität und seine verwendungen.
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
EP0288088B1 (en) 1987-04-24 1994-03-09 Teijin Limited Detection of tumor necrosis factor; monoclonal antibody and kit
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
ATE309376T1 (de) 1990-06-28 2005-11-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures

Also Published As

Publication number Publication date
EP2230307A1 (en) 2010-09-22
AU731553B2 (en) 2001-04-05
ES2248823T5 (es) 2011-11-03
EP1577391A1 (en) 2005-09-21
CA2266439A1 (en) 1998-05-07
KR20050004269A (ko) 2005-01-12
DE69635088T2 (de) 2006-06-14
JP2001503263A (ja) 2001-03-13
AU7674596A (en) 1998-05-22
EP0939804B2 (en) 2011-06-15
WO1998018921A1 (en) 1998-05-07
NZ334309A (en) 2000-08-25
BR9612752A (pt) 2000-01-18
DK0939804T3 (da) 2005-12-19
CN1539970A (zh) 2004-10-27
ES2248823T3 (es) 2006-03-16
PT939804E (pt) 2005-11-30
ATE302272T1 (de) 2005-09-15
EP0939804B1 (en) 2005-08-17
DE69635088T3 (de) 2012-01-26
EP0939804A1 (en) 1999-09-08
CA2665133A1 (en) 1998-05-07
CA2266439C (en) 2009-06-16
DE69635088D1 (de) 2005-09-22
KR20000052796A (ko) 2000-08-25

Similar Documents

Publication Publication Date Title
DK0939804T3 (da) Neutrokin-alpha
ATE365796T1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
DE69841140D1 (de) Interleukin-17 rezeptor-ähnliches protein
WO1998031806A3 (en) Fc receptors and polypeptides
WO1998033920A3 (en) Tissue factor pathway inhibitor-3
NZ510367A (en) Interleukin 17-like receptor protein nucleic acid sequence encoding the interleukin receptor protein and method of expressing protein in recombinant vector
WO1998031818A3 (en) Tace-like and matrilysin-like polypeptides
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
DE69836956D1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
EP1003767A4 (en) TR10 RECEPTOR OF HUMAN TUMOR NECROSIS FACTOR
WO2000067793A8 (en) Death domain containing receptor 4
WO2004039940A3 (en) Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
HK1042498A1 (zh) 肿瘤坏死因子受体6α及6β
ATE472599T1 (de) Chemokin alpha-5
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.
WO2001032128A3 (en) Human chemokine beta-13
WO2000039136A3 (en) Human brainiac-5
WO2002018622A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
DE60120507D1 (de) Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1
EP1712631A3 (en) Fc receptors and polypeptides
WO2003031566A3 (en) Keratinocyte derived interferon
WO2002074959A3 (en) Human leucine-rich repeat containing protein expressed predominately in nervous system tissues, hlrrns1
MXPA03005564A (es) Nueva proteina que contiene repeticiones ricas en leucina de humano que es expresada predominantemente en medula osea, hlrrbm1.
MX9801603A (es) Alteraciones geneticas relacionadas con la enfermedad de alzheimer hereditaria.